Handelsbanken Fonder AB Purchases 800 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Handelsbanken Fonder AB boosted its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 3.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,100 shares of the biopharmaceutical company’s stock after purchasing an additional 800 shares during the quarter. Handelsbanken Fonder AB’s holdings in Intra-Cellular Therapies were worth $2,263,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. True Wealth Design LLC purchased a new stake in Intra-Cellular Therapies in the third quarter valued at approximately $32,000. GAMMA Investing LLC raised its stake in Intra-Cellular Therapies by 46.3% in the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 240 shares in the last quarter. Capital Performance Advisors LLP purchased a new stake in Intra-Cellular Therapies in the third quarter valued at approximately $74,000. Venturi Wealth Management LLC purchased a new stake in Intra-Cellular Therapies in the fourth quarter valued at approximately $96,000. Finally, Wilmington Savings Fund Society FSB purchased a new stake in Intra-Cellular Therapies in the third quarter valued at approximately $97,000. 92.33% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Leerink Partnrs downgraded shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Mizuho downgraded shares of Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $140.00 to $132.00 in a research note on Monday. Cantor Fitzgerald raised shares of Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 14th. Canaccord Genuity Group downgraded shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and lifted their price target for the stock from $119.00 to $132.00 in a research note on Friday, January 31st. Finally, Royal Bank of Canada reissued a “sector perform” rating and set a $132.00 price target (up from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Ten equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Intra-Cellular Therapies currently has a consensus rating of “Hold” and a consensus target price of $106.08.

Insider Activity at Intra-Cellular Therapies

In related news, CEO Sharon Mates sold 51,000 shares of Intra-Cellular Therapies stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total value of $4,375,800.00. Following the sale, the chief executive officer now owns 1,070,329 shares in the company, valued at $91,834,228.20. The trade was a 4.55 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 2.60% of the stock is currently owned by company insiders.

Intra-Cellular Therapies Stock Performance

Shares of Intra-Cellular Therapies stock opened at $128.57 on Tuesday. Intra-Cellular Therapies, Inc. has a 52-week low of $63.30 and a 52-week high of $128.77. The stock has a market capitalization of $13.67 billion, a price-to-earnings ratio of -147.78 and a beta of 0.72. The company’s 50 day moving average price is $111.14 and its 200-day moving average price is $90.22.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The firm had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. As a group, equities research analysts forecast that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.